and Lucy, quarter everybody, second call. you, to Thank our welcome,
like First state to also our epidemic is the we I'd COVID to at business. going briefly off, of of look to it where the has the back through call, kind a go will on QX quick that or started have the have impact and we're which
we're middle terms a were but we remember, As in by actually overall also an you stabilization recovered see number that the of the we the more increased we of due that in from fluctuations into levels that that of vaccination, may our of get And should and that year, environment middle we waves QX actually up a hopeful did reach the guide by we level cycles of just of we actually to overall and able COVID or ramp patients our should for to year. COVID more where enrollment place get the obviously guide this us have did to stability predictable expecting that trials. a that substantial having people we should stable more enrolling start were of into so be ebb infection, environment also to COVID of a to
reality what we were We is are for to pleased very today. a hoping say actually indeed that
level in and the very think, of of I studies. who've in us vaccinated do at between clinical conduct infection, that, think reached XX% actually terms the have UK from the stability that level of the a the in people well U.S. about now people helpful is and actually same I as gives we a as of recovered base
seen see do impact of the we they surges also obviously indeed be there year, than in the the to we seen certain and actually of a while we more all quickly vaccines what much reflection had fact, fact that that and are earlier Now, great are seem places Delta but I curved doing the job that in in a [indiscernible]. very think have nicely nice the are variant, they
with key number this quick giving on actually A go As also keep news, us activities hoping, to studies. timelines us we very on into the pipeline. we on that were and allow trials. our increase X. If actually and that And to key the good up rate will our think allow the track I the update regards Slide and were to just we did on ramp to enrollment obviously, obviously, is,
First the obe-cel. on activities off, obviously,
FELIX is that we progressing Our course will next pivotal guidance we're data reiterating year. the our during of study deliver well, of and
us Now, what lymphoma. an non-Hodgkin's the And just at years. level patients were in to in in that of and at in therapy a more is a opportunity survival to additional indeed, obe-cel of very the actually now actually were trial with indeed, time effect first in that inventory in months, patients stabilizing for is a This above suggestive ALL, than least at was this we news update subset been we've now population, this In it see good frankly, transformational ALL, we patient extended quite XX months. experiences of have only because a look not able treating. XX%, and to really the that patients, actually of we the clear that but was sustained also a this durable may quarter, have XX over able observation two gives we hint
So to as really where own has the of level think the point that's a actually data I now matters validity program. news. data a very starts of terms the that to actually well our It's of mature in good obviously view
of very non-Hodgkin's CR also, In follicular particularly to did levels metabolic lymphoma, with we look cell we patients high data present did and on able addition, lymphoma, obviously, are mantle rates. or lymphoma, show
safety and fact, with very patients metabolic In good CRs achieved all a profile. also combined
that features with we're associated data we addition in of this at Cancer, ALL key starting had long update to looking durability publication are maybe obviously, the some in effect see Nature that that of EHA at a the patients. Now, to, in also product
Now, side. the moving regulatory to
the think key events in second were two happening the that quarter. I
designation to with allows key process, through beyond Health in Service therapies, actually patients. the UK program this that as and And which pivotal actual is, PRIME it the engagement the to do did with that. to into well that First, did so-called is we players receive really Agency, MHRA. key moving when gives us ability the and European also Medicine's process preferred as regulatory did actually also, only gives the the an what Agency, Healthcare but and to the from then not receive helpful PRIME for an further engage Europe, actually designation, UK with that a quite it with you a It National approval. preferred really actually the we're ultimately very to which – NICE, we regulatory body, the us be designation body the you an frankly, ILAP approach the in regulatory you look stage in as which what similarly review we should program, allows the second goes so-called designation we And towards through and the Medicines but for from access innovative ability and gives get the to you
were believe, obviously developments, important data and actually can the those us the with and So able of because generate far. very very path a reflection we we we the that good so gives are a program, it that projection take are to
the have As initially guidance course data also, have the I as indicated we reiterating we to XXXX before. pivotal our of guided during are
think obviously, giving for additional from part indicated, an on receive ILAP of will data going As that the obviously, finally, be year. also AUTOX, is that that us, gives flow we relapsed/refractory, in opportunity data to the MHRA, again we helpful the forward. preferred an encouraging, designation the access and us And believe obe-cel program did on very I later
Slide to X. Moving
corporate on Just a update side. quick the
development happened actually would a experience the that Murphy the as Sales million which And now activities off, into additional change the as including, about very and R&D just We organization that companies, the Dr. the Chief quarter. ADSs quarter, new long the First Novartis' had very of $XX.X and of the over Edgar Market we Chairman stay netted company. million we're period sold to at in of the appointment of joined has a post the Open – course of range had in updates, amount Chairman I the well. excited Martin during say, during a July Braendle, in announce look tremendous has context Officer role. us in Edgar has significant we a Development in of we the course taken X non-executive Agreement had when the of under company. who levels capital of very as
are with to actually, Moderna, we addition, Wolfram improved engineering of running Head the In announce types early Moderna Monjuvi a he binders focused, of developed MorphoSys recognition RNA approaches properties, be or our finally, program tafasitamab company. – as This are the it's the approaches we've to us the that did where and and us nice base was and a kind clinical And in on that with at the in unique the from Agreement very patients. program of working recently, in of where Clinical used, programs of obviously, Development. those diffused related License an context particularly joined the on. technology binders the then Wolfram Option that Brugger is lymphoma of of considered isn't new platform particularly was obviously, obviously, capabilities week joined large subset B-cell
like I are well ALL, focus sort to to obviously, study FELIX includes have And are not our as patients on patients patients a setting, So, as blinatumomab. to to Autolus blinatumomab relapsed briefly post reset which relapsed/refractory we're thoughts with of you yet but in as Slide both actually with X. that but good just as remember, adult move key is experienced well with regards what that, inotuzumab, think do that as ALL. or switch in gears, delivering just inotuzumab the And is I'd
that So in two subpopulations we we're have looking at particular this actually trial.
pediatric And CLL, the activity just with actually that of in the cell also cohorts. the then As exploring patients of towards building ALL, in CDXX patients, where which adds that backbone we for study on patients do mantle are children beyond with addition novel planning that the data the we're AUTOX/XX, the mentioned, with treating receptor evaluating antigen now a on follicular we And ALL. or in and the update AUTOX just actually additional with of are to the include of we we obe-cel, evolution then first obe-cel is DLBCL program obe-cel or and year. and that additional as the an of program, context AUTOX end we product we're ALLCARXX will released chimeric we
I'd X. status of with that like of to that I as some Slide and X, currently So standard are in Slide ALL to just with and on And it's think, to this that, indication. the indication important the see an features move key, care we regards
a think population the I the with We're for patients. off, This will the looking most therapy. an frontline the a somewhere ALL, that, achieve actually of remission only achieve the about important to patients XX% adult in it's XX% fact First to long-term of XX%, ability patients between is realize of to at that despite complete benefit. particularly actually percentage a have smaller
actually most remission. of for not long-term these translate complete remission, However, that into patients does a
very induction of and them chemotherapy would So After and high-dose high-dose they after, of relapse eventually then get when actually followed cycles through by having intense patients go consolidation. that relapse, gone stem obviously, transplant. cell through do additional many on chemotherapy,
a that although And cell relapse patient cure getting on with of gets to really actually with to the certain a there in majority are We about average, the standard U.S., blinatumomab. However, transplant very, XX% difficult blinatumomab still is so in the currently still us chance see very starting limited field, stem we the of time population of is in available. that's will very the the looking patients spot really care, transplant, a in is again. on concentrate receiving on have that particularly to at or of that, the the U.S. this patients patients What these indeed, very,
actually the remissions it However, in is relapsed/refractory does patients active, long-term setting. not convey blinatumomab the in although,
have good event-free think as that a good a what at is that that, induced set to have therapy we're to benefit-risk levels the perspective the lot about look on into think, the that the high obviously, we starting general event-free over managing of obviously, programs challenging I then with have, long-term CAR-T the stabilizing is we indeed, of adult sense a a patients with in CAR-T That a in looking properties EHA the curve safety when And, type move side, fact but gives this where, proportion We actually actually these survival. very that presented this And are positioning obviously, were have a obviously, of set we we're very moving is already highly that So very that when seeing, now ultimately there communicated, that of therapy. our least population opportunity us can Key actually of point chance seen itself. therapy of we receive, have a regulatory We a start. that obviously, now responses. adverse where of at X. that program. a we're in and Slide have into by I profile, it's line of we're remissions. indeed, we the we see challenging the best with we And an designations. the think of talked at ALL is about attractive time. up update getting type we just approaches we events that with we the is, getting around progression the get we a did this from first really the believe place seeing survival That product a a
XX. to Moving Slide
CAR-T I want fact believe remission. in And tenfold of actually before which make been correlated our with stabilization see to the that, able time. response in over actual but quite cells to we a absolute the indicated, of programs, think that are in time. actually from the of disease ALLCAR do is the the unique, event-free point of hasn't And cells level above maintain setting, CAR-T molecular to long-term I the CAR-T the the that, we survival, level to knowledge, about over shown exceptional patient, this seeing is, we the able the with reported but increase about as study a we're of persistence have be translate also been tenfold in cells programs, maximum do Not also number a that product. see in that to the actually other CAR-T event the the prerequisite which only are – a that is both and cells formed actually clearly, into over sustained other data we
profile, it On the side, event right-hand have we the you basically reported earlier. adverse see as
haven't go often have vasopressors. think ICU I note sort into And for didn't related used need patients, the adverse these of And that, syndrome. received of the the obviously, was to important that it's treatment therapies important what CAR-T managed. to to patients that tells the events actually patients look that be release what's related is with when vasopressors stabilize to and see also CAR-T to none to you the actually the to is, cytokine quite you we seen therapy, high-grade manage
So It's and a it it's profile. gives very a profile. very us good unique safety well manageable, efficacy very
Moving a This to look some we're in space. quick XX. data just at now of Slide that the this seeing is
right have, blinatumomab datasets now ASCO and and published at ALL, in the approvals also We were also inotuzumab. time, company basis the as a as obviously, well Tecartus also filing adult same have, BLA for we that then foundation And from the made. for the the data at of presented that relapsed/refractory the the
safety datasets, And, of against it long-term have look space. the stack at, That programs. these from overall, profile, does to do certainly, we all product event-free data the a when nicely we advantageous differentiated as as we that comes actually very we which up these when see So we impact, to very believe well see obe-cel this will survival very a survival. at give event-free overall well in us
is FELIX This patients. about Moving study. to obviously, the before, did Slide XX. study study, relapsed/refractory XXX-patient mention I
response. the the The event-free This As are the to of onto the swing presentation responses endpoint to secondary is we the primary patients lymphoma well inotuzumab, or as regards the post complete includes looking as response as exposure that endpoints were word a non-Hodgkin's referenced molecular relapsed/refractory inexperienced of who indicated overall blina rate, two data survival and plot Quick as or nine before at, with that and subpopulations the were blina well in patients. and inotuzumab. study that is patients of I duration of at EHA. dosed are subject
As you all patients form remission, these None of complete the high-grade CRS. experienced can profile safety was very see, had the patients and neurotoxicity. of Nobody achieved of positive. a metabolic any a
developed of COVID. as remission, in metabolic obviously, skin progression COVID and a patient event which be one died lesion The will who contracted that recorded actually basically as the event, patient well was complete a patient is But which a be in that of the unfortunately, in consequence and could sad way. to patients, removed as One a have very that died surgically. lesion
XX. number Slide Now
word Just of exploration sort out on activity obe-cel ongoing of now, a the the quick of actually that indications. the round across a of activities range
As patients as do you the in we as extension the non-Hodgkin's before, lymphoma the evaluate ALLCARXX as of patients part indicated study. I CLL well of activity to
we of that ALL malignancies. in positive of us of And good the range give these see in range also study, patients We across partners, very the overview of that our DLBCL, exclusively to similar collaboration obviously, we lymphoma already which brain. over are CARPALL conducting is an programs with mentioned, an academic the as CDXX all aggressive a have in essence, will conducting is AUTOX/XX which then that extension CNS And lymphoma, in in the a activity patients. are the with study CAROUSEL localized pediatric primary study is,
to Slide XX. Moving
to program. side, continue cell T the we escalate the lymphoma dose On AUTOX
We first of program, period to which entry be we next part the data at going of expect alongside on update progress study expect occur year. – one the the data time program, first And the time. provide we'll update, the that be in AUTOX half in of also the AUTOX first obviously, the we're of will the and for the XXXX, same in will to conferences on the
are business. on a aspect company This And IP with on unique in one one Now in outcome, obe-cel with obviously, technology setting. key you the as collaboration elements of XX, that, is gives is key type largest the which a on us do persistence, a of in reminder very Slide clinical the key estates very did now obviously that And strong base technology the using of quick obe-cel of feature what in obviously, has see all very you in that this side differentiation. a different safety. of both efficacy, probably differentiated that of that set one the just our – binder binder in the really now to remember overall we but Moderna also of on elements that used related products a Moderna is the is unique case properties, the of technology the obviously,
to Now XX. moving Slide
program I AUTOX/XX obviously, and AUTOXNG broader forward. moving AUTOX program. the already, here, is So the indicated
are quite programmed this up in able guided product program. and academic expect preparing obviously, the in AUTOX to AUTOX and of have we as the we before, We is, clinics XXXX. had be trial obviously, then half part also And to of advanced with the early XXXX, running an this
lead with who Thank that, to I'd through our you. will hand over Now financial results. to like actually Andrew, you
